Disease relevance of Neutron Capture Therapy

• Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas [1].
• Accumulation of boron-10 (10B) in cell cultures exposed to mercaptododecaborate (Na2H(11)10B12SH) used for the neutron capture therapy of brain tumors [2].

High impact information on Neutron Capture Therapy

• Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy [3].
• Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system [4].
• The results show that the boron-conjugated antibodies retain selective localization in the tumors, thus indicating their suitability for transporting boron-10 to tumors for use in neutron-capture therapy of cancer [4].
• Neutron capture therapy with L-10BPA caused a reduction in tyrosine hydroxylase immunohistochemical activity within 4 h of irradiation, but by 48 h, this reduction reversed [5].
• The purpose was to evaluate the possible efficacy of chlorpromazine, which is known to bind to melanin, as a vehicle for boron transport in neutron capture therapy [6].

Chemical compound and disease context of Neutron Capture Therapy

• Gadolinium neutron capture therapy for brain tumors: a computer study [7].
• Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7) [8].
• The water-soluble free-base derivative, tetrakiscarborane carboxylate ester of 2,4-(alpha,beta-dihydroxyethyl) deuteroporphyrin IX (BOPP), an agent designed for neutron capture therapy, has previously demonstrated selective localization and retention in a C6 murine glioma [9].

Anatomical context of Neutron Capture Therapy

• Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy [10].

Associations of Neutron Capture Therapy with chemical compounds

• Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI [11].
• Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy [12].
• To evaluate the possible usefulness of partially deuterated water in neutron capture therapy (NCT), neutron flux density distributions were measured in a 23 x 16.5 cm (length x diameter) cylinder for incident thermal and epithermal neutron beams, at 20 and 40 at. % deuteration of water [13].
• CONCLUSION: The sulforhodamine-B assay is suitable for the screening of compounds for potential use in neutron capture therapy because it is a fast and efficient method that is reproducible and technically advantageous [14].
• Boron-containing estrogens may be useful for thermal neutron capture therapy of cancers with estrogen receptors to concentrate boron in the cell nucleus [15].

Gene context of Neutron Capture Therapy

• The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors [16].
• Boron-containing folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy [17].
• The possibilities to combine proton beams with EGF-guided neutron capture therapy will be considered in a longer perspective [18].
• In an example case of Gd Neutron Capture Therapy (GdNCT), a 1 cm radius midline tumor, peak normal tissue dose of 10 Gy, and a tumor concentration of 1000 ppm Gd, result in a maximum of 140 +/- 27 DSBs per tumor cell [19].
• Thymidine analogs containing carboranylalkyl groups for neutron capture therapy at the N-3 position were found to be good substrates for cytosolic thymidine kinase 1 (TK1) [20].

Analytical, diagnostic and therapeutic context of Neutron Capture Therapy

• Finally, contrast agents conjugated with either monoclonal antibodies or with avidin are able to function as tumor-specific contrast agents and might also be employed as therapeutic drugs for either gadolinium neutron capture therapy or in conjunction with radioimmunotherapy [21].
• A comparison of the COG and MCNP codes in computational neutron capture therapy modeling, Part I: boron neutron capture therapy models [22].

References